Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the Phase 3 GRAVITI study
Key Points
The aim is to evaluate the efficacy and safety of subcutaneous guselkumab in East Asian participants with Crohn's disease.
Subgroup analysis from the Phase 3 GRAVITI study
Focused on moderately to severely active Crohn’s disease
Compared results with the global study outcomes
Efficacy and safety findings align with global study results
Subcutaneous guselkumab demonstrated effectiveness for Crohn’s disease
Safety profile found consistent across populations
Abstract
Efficacy and safety results of SC guselkumab in East Asian participants with moderately to severely active CD reflect findings from the global study.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the Phase 3 GRAVITI study | Synapse